Proprietary AI analyst is now available
- Public Comps
- Ackermans & Van Haaren
Ackermans & Van Haaren Valuation Multiples
Discover Ackermans & Van Haaren's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Sofina, Bajaj Holdings & Investment Limited, Nippon Life India Asset, Compagnie du Cambodge and more.
Ackermans & Van Haaren Overview
About Ackermans & Van Haaren
Ackermans & Van Haaren NV is an investment company with five core business segments: Marine Engineering and Contracting, Private Banking, Real Estate, Energy and resources, and AvH and Growth Capital. The company has a long-term, activist orientation focused on making investments in growth companies with international exposure. A plurality of its net profit mix is derived from its Marine Engineering & Contracting segment, followed closely by its Private Banking & Real Estate division.
Founded
1924
HQ

Employees
24.4K
Website
Sectors
Financials (LTM)
EV
$20B
Valuation Multiples
Start free trialAckermans & Van Haaren Financials
Ackermans & Van Haaren reported last 12-month revenue of $7B and EBITDA of $1B.
In the same LTM period, Ackermans & Van Haaren generated $1B in EBITDA and $707M in net income.
Revenue (LTM)
Ackermans & Van Haaren P&L
In the most recent fiscal year, Ackermans & Van Haaren reported revenue of $7B and EBITDA of $2B.
Ackermans & Van Haaren is profitable as of last fiscal year, with gross margin of 38%, EBITDA margin of 25%, and net margin of 10%.
Financial data powered by Morningstar, Inc.
Ackermans & Van Haaren Stock Performance
Ackermans & Van Haaren has current market cap of $10B, and enterprise value of $20B.
Market Cap Evolution
Ackermans & Van Haaren's stock price is $304.40.
Ackermans & Van Haaren share price decreased by 4.0% in the last 30 days, and increased by 21.6% in the last year.
Ackermans & Van Haaren has an EPS (earnings per share) of $21.40.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20B | $10B | -0.1% | -4.0% | -1.8% | 21.6% | $21.40 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAckermans & Van Haaren Valuation Multiples
Ackermans & Van Haaren trades at 2.8x EV/Revenue multiple, and 14.2x EV/EBITDA.
EV / Revenue (LTM)
Ackermans & Van Haaren Financial Valuation Multiples
As of June 5, 2026, Ackermans & Van Haaren has market cap of $10B and EV of $20B.
Ackermans & Van Haaren has a P/E ratio of 14.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ackermans & Van Haaren Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ackermans & Van Haaren Margins & Growth Rates
Ackermans & Van Haaren decreased revenue by 1% and EBITDA by 23% in the last fiscal year.
In the most recent fiscal year, Ackermans & Van Haaren reported gross margin of 38%, EBITDA margin of 25%, and net margin of 10%.
Ackermans & Van Haaren Margins
Ackermans & Van Haaren Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ackermans & Van Haaren Operational KPIs
Ackermans & Van Haaren's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Ackermans & Van Haaren's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ackermans & Van Haaren's Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Ackermans & Van Haaren Competitors
Ackermans & Van Haaren competitors include Sofina, Bajaj Holdings & Investment Limited, Nippon Life India Asset, Compagnie du Cambodge, Brookfield Business Corp, TPG, Ares Capital, Onex, EXOR and 3i Infrastructure.
Most Ackermans & Van Haaren public comparables operate across PE & VC.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 49.4x | - | - | - | |||
| 11.0x | - | - | - | |||
| 25.2x | 24.5x | 35.6x | 38.2x | |||
| 37.3x | - | 106.0x | - | |||
| 1.7x | - | 6.6x | - | |||
| 3.0x | 4.1x | 8.6x | 7.8x | |||
| 9.6x | 9.6x | 8.1x | 8.1x | |||
| 7.1x | - | 9.9x | - | |||
This data is available for Pro users. Sign up to see all Ackermans & Van Haaren competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Ackermans & Van Haaren
Ackermans & Van Haaren has acquired 1 company to date.
Last acquisition by Ackermans & Van Haaren was on February 22nd 2019. Ackermans & Van Haaren acquired Biolectric for $18M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Ackermans & Van Haaren
| Description | Biolectric is a bioenergy producer enabling durable power generation that aligns supply with demand. |
| HQ Country | |
| HQ City | Temse |
| Deal Date | 22 Feb 2019 |
| Valuation | $18M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Ackermans & Van Haaren acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by Ackermans & Van Haaren
Ackermans & Van Haaren has invested in 8 companies to date.
Latest investment by Ackermans & Van Haaren was on December 11th 2025. Ackermans & Van Haaren invested in DISCO Pharmaceuticals in their $42M Seed round (EV/Revenue multiple available to Pro users).
Latest Investments by Ackermans & Van Haaren
| Description | DISCO Pharmaceuticals is a biotech company mapping surface proteins on cancer cells through large-scale surfaceome analysis. Its proprietary platform identifies novel targets for antibody-drug conjugates in solid tumors. Munich-based DISCO Pharmaceuticals advances precision oncology therapies using mass spectrometry and bioinformatics. | MRM Health NV is a Ghent-based biopharmaceutical company developing microbiome therapeutics for inflammatory bowel diseases. Incorporated in 2020 as a VIB spin-off, it leverages MRM Technologies' expertise in microbial consortia screening. Lead candidates target ulcerative colitis and Crohn's disease through oral live biotherapeutic products in preclinical stages. | Confo Therapeutics is a biopharma company developing GPCR-targeted therapeutics using its CONFO platform to stabilize active receptor conformations for agonist discovery. Programs address unmet needs in respiratory, cardiovascular, and neurological diseases. Founded in 2015 and based in Brussels, Belgium, it partners with major pharma firms like Janssen and Boehringer Ingelheim. | Vico Therapeutics is a Leiden-based clinical-stage biotechnology company developing antisense oligonucleotide therapies for rare neurological disorders. Its lead candidate VIC-101 targets spinocerebellar ataxia type 2 and entered phase 1/2 clinical trials in 2023. The pipeline also includes programs addressing amyotrophic lateral sclerosis and Huntington's disease, stemming from technology licensed from uniQure in 2019. | |
| HQ Country | |||||
| HQ City | Cologne | Ghent | Brussels | Leiden | |
| Deal Date | 11 Dec 2025 | 4 Sep 2025 | 26 Jul 2024 | 24 Jun 2024 | |
| Round | Seed | Series B | Series B | Series B | |
| Raised | $42M | $65M | $65M | $12M | |
| Investors | AbbVie; Ackermans & Van Haaren; M Ventures; NRW.BANK; Panakes Partners; Sofinnova Partners | Ackermans & Van Haaren; Athos; BIOCODEX; BNP Paribas Fortis; OMX Ventures; QBIC II; SFPIM; VIB | Ackermans & Van Haaren | Ackermans & Van Haaren; Droia Ventures; EQT; Eurazeo; Kurma Partners; Polaris Partners; Pureos Bioventures; Seroba Life Sciences | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Ackermans & Van Haaren investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ackermans & Van Haaren
| When was Ackermans & Van Haaren founded? | Ackermans & Van Haaren was founded in 1924. |
| Where is Ackermans & Van Haaren headquartered? | Ackermans & Van Haaren is headquartered in Belgium. |
| How many employees does Ackermans & Van Haaren have? | As of today, Ackermans & Van Haaren has over 24K employees. |
| Is Ackermans & Van Haaren publicly listed? | Yes, Ackermans & Van Haaren is a public company listed on Euronext Brussels. |
| What is the stock symbol of Ackermans & Van Haaren? | Ackermans & Van Haaren trades under ACKB ticker. |
| When did Ackermans & Van Haaren go public? | Ackermans & Van Haaren went public in 1984. |
| Who are competitors of Ackermans & Van Haaren? | Ackermans & Van Haaren main competitors include Sofina, Bajaj Holdings & Investment Limited, Nippon Life India Asset, Compagnie du Cambodge, Brookfield Business Corp, TPG, Ares Capital, Onex, EXOR, 3i Infrastructure. |
| What is the current market cap of Ackermans & Van Haaren? | Ackermans & Van Haaren's current market cap is $10B. |
| What is the current revenue of Ackermans & Van Haaren? | Ackermans & Van Haaren's last 12 months revenue is $7B. |
| What is the current revenue growth of Ackermans & Van Haaren? | Ackermans & Van Haaren revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Ackermans & Van Haaren? | Current revenue multiple of Ackermans & Van Haaren is 2.8x. |
| What is the current EBITDA of Ackermans & Van Haaren? | Ackermans & Van Haaren's last 12 months EBITDA is $1B. |
| What is Ackermans & Van Haaren's EBITDA margin? | Ackermans & Van Haaren's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Ackermans & Van Haaren? | Current EBITDA multiple of Ackermans & Van Haaren is 14.2x. |
| What is the current FCF of Ackermans & Van Haaren? | Ackermans & Van Haaren's last 12 months FCF is $610M. |
| What is Ackermans & Van Haaren's FCF margin? | Ackermans & Van Haaren's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Ackermans & Van Haaren? | Current FCF multiple of Ackermans & Van Haaren is 32.0x. |
| How many companies Ackermans & Van Haaren has acquired to date? | As of June 2026, Ackermans & Van Haaren has acquired 1 company. |
| What was the largest acquisition by Ackermans & Van Haaren? | $18M acquisition of Biolectric on 22nd February 2019 was the largest M&A Ackermans & Van Haaren has done to date. |
| What companies Ackermans & Van Haaren acquired? | Ackermans & Van Haaren acquired Biolectric. |
| In how many companies Ackermans & Van Haaren has invested to date? | As of June 2026, Ackermans & Van Haaren has invested in 8 companies. |
| What was the last Ackermans & Van Haaren investment? | On 11th December 2025 Ackermans & Van Haaren invested in DISCO Pharmaceuticals, participating in a $42M Seed round, alongside AbbVie, M Ventures, NRW.BANK, Panakes Partners, and Sofinnova Partners. |
| In what companies Ackermans & Van Haaren invested in? | Ackermans & Van Haaren invested in Vico Therapeutics, Confo Therapeutics, Medikabazaar, MRM Health NV, DISCO Pharmaceuticals, Biotalys, AstriVax, and OncoDNA. |
See public comps similar to Ackermans & Van Haaren
Lists including Ackermans & Van Haaren
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


